SG11202112229UA - Cdk inhibitors - Google Patents
Cdk inhibitorsInfo
- Publication number
- SG11202112229UA SG11202112229UA SG11202112229UA SG11202112229UA SG11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA SG 11202112229U A SG11202112229U A SG 11202112229UA
- Authority
- SG
- Singapore
- Prior art keywords
- cdk inhibitors
- cdk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019085494 | 2019-05-05 | ||
| PCT/CN2020/088585 WO2020224568A1 (fr) | 2019-05-05 | 2020-05-05 | Inhibiteurs de cdk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112229UA true SG11202112229UA (en) | 2021-12-30 |
Family
ID=73051265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112229UA SG11202112229UA (en) | 2019-05-05 | 2020-05-05 | Cdk inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220296595A1 (fr) |
| EP (2) | EP3966213A4 (fr) |
| JP (2) | JP2022531687A (fr) |
| KR (1) | KR20220004755A (fr) |
| CN (3) | CN114364675A (fr) |
| AU (2) | AU2020269469A1 (fr) |
| BR (1) | BR112021022105A2 (fr) |
| CA (1) | CA3138973A1 (fr) |
| CL (1) | CL2021002903A1 (fr) |
| CO (1) | CO2021016504A2 (fr) |
| EA (1) | EA202193015A1 (fr) |
| IL (1) | IL287767A (fr) |
| MA (1) | MA55909A (fr) |
| MX (1) | MX2021013531A (fr) |
| SG (1) | SG11202112229UA (fr) |
| TW (2) | TW202108572A (fr) |
| WO (2) | WO2020224568A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
| JP2022519205A (ja) * | 2019-01-29 | 2022-03-22 | ベータ・ファーマ・インコーポレイテッド | 脳腫瘍および脳転移の治療剤としての２ｈ－インダゾール誘導体 |
| AU2020269469A1 (en) * | 2019-05-05 | 2021-12-09 | Regor Pharmaceuticals, Inc. | CDK inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AU2021382769B2 (en) * | 2020-11-20 | 2024-03-07 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Dihydroisoquinolinone and isoindolinone derivatives and uses thereof |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023143482A1 (fr) * | 2022-01-29 | 2023-08-03 | 上海辉启生物医药科技有限公司 | Composé ou sel de 2-aminopyrimidine, son procédé de préparation et son utilisation |
| WO2023196517A1 (fr) * | 2022-04-08 | 2023-10-12 | Biolexis Therapeutics, Inc. | Inhibiteurs de cdk9 |
| CN117645604A (zh) * | 2022-09-05 | 2024-03-05 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| WO2024107746A1 (fr) * | 2022-11-15 | 2024-05-23 | Larkspur Biosciences | Inhibiteurs et agents de dégradation de protéine pip4k |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2463989C (fr) * | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Derives pyrimidine, compositions pharmaceutiques contenant ces composes, utilisation et procede de fabrication de ces composes |
| US8258129B2 (en) * | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| TWI675028B (zh) * | 2014-07-24 | 2019-10-21 | 美商貝達醫藥公司 | 做為週期素依賴型激酶（ｃｄｋ）抑制劑之2-ｈ-吲唑衍生物及其醫療用途 |
| CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| CN107428731B (zh) * | 2015-03-11 | 2020-05-05 | 正大天晴药业集团股份有限公司 | 作为抗癌药物的取代的2-氢-吡唑衍生物 |
| CN108602799B (zh) * | 2016-02-06 | 2021-08-03 | 上海复尚慧创医药研究有限公司 | 一类激酶抑制剂 |
| CN107286134B (zh) * | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
| LT3442947T (lt) * | 2016-04-15 | 2023-09-11 | Epizyme, Inc. | Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai |
| WO2018045957A1 (fr) * | 2016-09-07 | 2018-03-15 | 江苏豪森药业集团有限公司 | Inhibiteur de cdk4/6, son procédé de préparation et son application |
| AU2017379041B2 (en) * | 2016-12-22 | 2021-08-26 | Betta Pharmaceuticals Co., Ltd | Benzimidazole derivatives, preparation methods and uses thereof |
| CN108264512B (zh) * | 2016-12-30 | 2022-05-03 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、其制备方法、中间体、组合物和应用 |
| CN108794452B (zh) * | 2017-05-05 | 2021-05-28 | 上海时莱生物技术有限公司 | 具有激酶抑制活性的化合物、其制备方法和用途 |
| CN109503573A (zh) * | 2017-09-14 | 2019-03-22 | 昆明圣加南生物科技有限公司 | 2-取代苯胺基嘧啶衍生物及其用途 |
| US10519136B2 (en) * | 2017-12-29 | 2019-12-31 | Accutar Biotechnology | Dual inhibitors of PARP1 and CDK |
| BR112020015405A2 (pt) * | 2018-01-29 | 2020-12-08 | Beta Pharma, Inc. | Compostos de 2h-indazóis como inibidores cdk4 e cdk6, composições farmacêuticas que os compreendem, seus usos terapêuticos e métodos de preparação |
| AU2020269469A1 (en) * | 2019-05-05 | 2021-12-09 | Regor Pharmaceuticals, Inc. | CDK inhibitors |
-
2020
- 2020-05-05 AU AU2020269469A patent/AU2020269469A1/en active Pending
- 2020-05-05 KR KR1020217039756A patent/KR20220004755A/ko unknown
- 2020-05-05 TW TW109114894A patent/TW202108572A/zh unknown
- 2020-05-05 BR BR112021022105A patent/BR112021022105A2/pt unknown
- 2020-05-05 CA CA3138973A patent/CA3138973A1/fr active Pending
- 2020-05-05 US US17/608,915 patent/US20220296595A1/en active Pending
- 2020-05-05 EA EA202193015A patent/EA202193015A1/ru unknown
- 2020-05-05 EP EP20802696.3A patent/EP3966213A4/fr active Pending
- 2020-05-05 JP JP2021565881A patent/JP2022531687A/ja active Pending
- 2020-05-05 CN CN202080049033.9A patent/CN114364675A/zh active Pending
- 2020-05-05 MX MX2021013531A patent/MX2021013531A/es unknown
- 2020-05-05 WO PCT/CN2020/088585 patent/WO2020224568A1/fr active Application Filing
- 2020-05-05 SG SG11202112229UA patent/SG11202112229UA/en unknown
- 2020-05-05 MA MA055909A patent/MA55909A/fr unknown
-
2021
- 2021-05-04 US US17/922,804 patent/US20230174512A1/en active Pending
- 2021-05-04 AU AU2021268648A patent/AU2021268648A1/en active Pending
- 2021-05-04 WO PCT/US2021/030728 patent/WO2021226140A1/fr unknown
- 2021-05-04 CN CN202180046122.2A patent/CN115803327B/zh active Active
- 2021-05-04 JP JP2022567388A patent/JP2023525005A/ja active Pending
- 2021-05-04 CN CN202410197266.3A patent/CN118406049A/zh active Pending
- 2021-05-04 EP EP21727336.6A patent/EP4146647A1/fr active Pending
- 2021-05-05 TW TW110116234A patent/TW202144351A/zh unknown
- 2021-11-01 IL IL287767A patent/IL287767A/en unknown
- 2021-11-04 CL CL2021002903A patent/CL2021002903A1/es unknown
- 2021-12-03 CO CONC2021/0016504A patent/CO2021016504A2/es unknown
-
2023
- 2023-09-26 US US18/373,067 patent/US20240033264A1/en not_active Abandoned
- 2023-09-26 US US18/373,060 patent/US20240066031A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004755A (ko) | 2022-01-11 |
| CO2021016504A2 (es) | 2022-01-17 |
| US20240033264A1 (en) | 2024-02-01 |
| CN114364675A (zh) | 2022-04-15 |
| EP3966213A1 (fr) | 2022-03-16 |
| MA55909A (fr) | 2022-03-16 |
| CN118406049A (zh) | 2024-07-30 |
| CN115803327B (zh) | 2024-02-13 |
| US20240066031A1 (en) | 2024-02-29 |
| BR112021022105A2 (pt) | 2021-12-28 |
| EP4146647A1 (fr) | 2023-03-15 |
| TW202108572A (zh) | 2021-03-01 |
| WO2020224568A1 (fr) | 2020-11-12 |
| EP3966213A4 (fr) | 2023-04-19 |
| AU2021268648A1 (en) | 2023-01-19 |
| US20230174512A1 (en) | 2023-06-08 |
| AU2020269469A1 (en) | 2021-12-09 |
| US20220296595A1 (en) | 2022-09-22 |
| IL287767A (en) | 2022-01-01 |
| CA3138973A1 (fr) | 2020-11-12 |
| MX2021013531A (es) | 2022-02-11 |
| CL2021002903A1 (es) | 2022-07-08 |
| WO2021226140A1 (fr) | 2021-11-11 |
| JP2023525005A (ja) | 2023-06-14 |
| CN115803327A (zh) | 2023-03-14 |
| EA202193015A1 (ru) | 2022-03-17 |
| TW202144351A (zh) | 2021-12-01 |
| JP2022531687A (ja) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| IL287767A (en) | cdk inhibitors | |
| IL290341A (en) | prmt5 inhibitors that cooperate with mta | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| ZA202106284B (en) | Rad51 inhibitors | |
| IL289914A (en) | enzyme inhibitors | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| IL289863A (en) | enzyme inhibitors | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL289783A (en) | enzyme inhibitors | |
| IL289778A (en) | enzyme inhibitors | |
| IL288306A (en) | Combined treatments using cdk inhibitors | |
| IL283309A (en) | rip1 inhibitors | |
| EP4289835A4 (fr) | Inhibiteur de cdk | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| EP3976797A4 (fr) | Inhibiteurs anti-crispr | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| EP3768256A4 (fr) | Inhibiteurs d'entrée pantropique | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |